Etodolac
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Etodolac: Acromesomelic dysplasia, Hunter-Thompson type
One-Sentence Summary
Etodolac is a nonsteroidal anti-inflammatory drug (NSAID), originally used for rheumatoid arthritis, osteoarthritis and related joint disorders. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, a rare inherited skeletal disorder. This prediction has 0 clinical trials and 0 publications behind it, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for etodolac is not available in the data compiled for this report. It is known to be an NSAID that inhibits cyclooxygenase (COX), with a preferential effect on COX-2. This reduces prostaglandin-driven inflammation and pain in joint disease.
Acromesomelic dysplasia, Hunter-Thompson type, is a rare skeletal dysplasia caused by mutations in the CDMP1/GDF5 gene. The defect lies in growth-factor signalling during bone and cartilage development. Etodolac’s COX inhibition does not act on this pathway, and no plausible mechanistic link is evident.
The high score (0.9997) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. At best, an NSAID might relieve joint pain symptomatically. It would not be expected to change the underlying developmental defect.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Etodolac has 20 valid registrations in India, all single-entity listings. Several products combine etodolac with other actives such as thiocolchicoside, paracetamol or tramadol. The licence records contain no approved-indication text. Five main plain-etodolac products are shown below.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 72346 | Etova 400 Tablet | Strip of 10 tablets | Ipca Laboratories Ltd |
| 73022 | Etova 200 Tablet | Strip of 10 tablets | Ipca Laboratories Ltd |
| 75459 | Edonix 600mg Tablet ER | Strip of 10 extended-release tablets | Ajanta Pharma Ltd |
| 72861 | Etornext-ER Tablet | Strip of 10 extended-release tablets | Alembic Pharmaceuticals Ltd |
| 73477 | Etosafe ER Tablet | Strip of 10 extended-release tablets | Wanbury Ltd |
All products are oral formulations.
Safety Considerations
- Disease-level contraindication signals (from the knowledge graph, not package insert text): hypertension and hypertensive disorders, kidney disease, liver disease, gallbladder disease, peptic ulcer disease (including active ulcer), blood coagulation disease, myocardial infarction and coronary thrombosis, hemoglobinopathy, and cardiovascular and heart disease.
- Drug Interactions: 221 interactions were identified in total. Those listed below are a sample of 20, and most carry a Moderate rating.
- Corticosteroids: hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide (Moderate)
- Acetylsalicylic acid (Moderate)
- Mesalazine and balsalazide (Moderate)
- Metformin, glimepiride, chlorpropamide, repaglinide (Moderate)
- Potassium citrate and potassium bicarbonate (Moderate)
- Picosulfuric acid and polyethylene glycol with electrolytes (Moderate)
- Famotidine, ranitidine, cimetidine, linaclotide (Minor)
Please refer to the package insert for the full set of warnings.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials or publications behind it. The target is a genetic developmental disorder, and etodolac’s COX-inhibiting mechanism has no apparent link to the GDF5 signalling defect. The score is likely a network-proximity artefact.
To proceed, the following is needed:
- Any preclinical or clinical evidence linking etodolac to GDF5-related skeletal dysplasia
- Detailed mechanism-of-action data for etodolac
- Package insert warnings and contraindications from the India regulatory source
- A clear case that symptomatic NSAID use would help this rare population, with cardiovascular, gastrointestinal and renal risks assessed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.